{
    "title": "Merck adds experimental COVID-19 therapy with OncoImmune deal",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8977625/Merck-adds-experimental-COVID-19-therapy-OncoImmune-deal.html",
    "date": "2020-11-23",
    "keywords": [
        "covid19",
        "merck",
        "inc",
        "cd24f",
        "carl",
        "drugmaker",
        "drug",
        "phase",
        "candidate",
        "therapy",
        "steroid",
        "gvhd",
        "oncoimmune",
        "deal",
        "control",
        "company",
        "addition",
        "portfolio",
        "series",
        "acquisition",
        "themis",
        "partnership",
        "ridgeback",
        "trial",
        "data",
        "show",
        "injection",
        "likelihood",
        "improvement",
        "risk",
        "failure",
        "death",
        "perlmutter",
        "research",
        "dexamethasone",
        "standard",
        "care",
        "president",
        "trump",
        "manufacturing",
        "capacity",
        "scale",
        "graft",
        "host",
        "disease",
        "leukemia",
        "stem",
        "cell",
        "development",
        "treatment",
        "molnupiravir",
        "pfizer",
        "biontech",
        "authorization",
        "vaccine",
        "friday",
        "reporting",
        "odonnell",
        "rosalba",
        "obrien"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}